Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 13/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028402 | 1.00 | MCHR1 (0.47) | MCHR1ADRA2ANPY5RHTR2CEPHX2 | |
| SCHEMBL5530648 | 0.91 | MCHR1 (0.50) | MCHR1ADRA2ANPY5RHTR1AADRA1A | |
| SCHEMBL5527692 | 0.91 | MCHR1 (0.50) | MCHR1ADRA2ANPY5RHTR1AADRA1A | |
| SCHEMBL4200706 | 0.89 | EPHX2 (0.53) | MCHR1ADRA2ANPY5REPHX2HTR1A | |
| SCHEMBL4200711 | 0.89 | EPHX2 (0.53) | MCHR1ADRA2ANPY5REPHX2HTR1A | |
| SCHEMBL4033619 | 0.89 | MCHR1 (0.56) | MCHR1ADRA2ANPY5REPHX2HTR1A | |
| SCHEMBL4195859 | 0.89 | MCHR1 (0.56) | MCHR1ADRA2ANPY5REPHX2HTR1A | |
| SCHEMBL4205452 | 0.88 | MCHR1 (0.50) | MCHR1ADRA2ANPY5REPHX2HTR1A | |
| SCHEMBL5523903 | 0.88 | MCHR1 (0.50) | MCHR1ADRA2ANPY5REPHX2HTR1A | |
| SCHEMBL4210374 | 0.88 | MCHR1 (0.49) | MCHR1ADRA2ANPY5RHTR1AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | MCHR1 1/4885ADRA2A 103/4885NPY5R 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.